Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients
NCT00005106 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to look at the effects of different anti-HIV drug combinations on body fat changes in HIV-positive patients who have never received anti-HIV therapy before.
Conditions Studied
Interventions
- DRUG Lamivudine
- DRUG Stavudine
- DRUG Nelfinavir mesylate
- DRUG Lamivudine/Zidovudine
- DRUG Abacavir sulfate
Study Locations (20)
Florida
- IDC Research Initiative — Altamonte Springs
- Children's Diagnostic Treatment Ctr — Fort Lauderdale
- Community Health Care — Fort Lauderdale
- Comprehensive Care Center — Fort Lauderdale
- Univ of Miami School of Medicine — Miami
- South Shore Hosp — Miami
- Orange County Health Dept — Orlando
- Immunity Care and Research Inc — Plantation
- Daniel Seekins — Tampa
California
- Longbeach Memorial Med Ctr — Longbeach
- Good Samaritan Hosp — Los Angeles
- THE Clinic — Los Angeles
- AIDS Healthcare Foundation — Los Angeles
- Maxine Liggins — Los Angeles
- UCLA Care Ctr — Los Angeles
- Highland Gen Hosp / San Francisco Gen Hosp — Oakland
- San Francisco Gen Hosp — San Francisco
Alabama
- Univ of Alabama at Birmingham — Birmingham
Arizona
- Arizona Clinical Research Ctr Inc — Tucson
District of Columbia
- Georgetown Univ Med Ctr — Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 1999-09 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005106
The ClinicalTrials.gov registry entry for NCT00005106 describes a study currently listed as completed. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaxo Wellcome, which has 18 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 5 interventions — of which Lamivudine is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00005106 reports 20 study locations spanning 5 distinct geographic areas — top geographies include Florida, California, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00005106 about?
NCT00005106 is a clinical study titled "A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients". The purpose of this study is to look at the effects of different anti-HIV drug combinations on body fat changes in HIV-positive patients who have never received anti-HIV therapy before.
What is the current status of trial NCT00005106?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 230 participants. The study started on 1999-09.
What conditions does trial NCT00005106 study?
This clinical trial studies the following conditions: HIV Infections. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00005106?
The interventions under investigation include: Lamivudine (DRUG), Stavudine (DRUG), Nelfinavir mesylate (DRUG), Lamivudine/Zidovudine (DRUG), Abacavir sulfate (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00005106?
This trial is sponsored by Glaxo Wellcome, which has 18 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00005106 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.